<DOC>
	<DOCNO>NCT00426816</DOCNO>
	<brief_summary>This study evaluate effect SB-649868 ( 10 , 30 mg 60 mg ) sleep continuity , PSG sleep recording , subjective sleep assessment , daytime cognitive function subject primary insomnia</brief_summary>
	<brief_title>To Evaluate The Effects Of SB-649868 ( 10 , 30 Mg And 60 Mg ) On Subjects With Primary Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Male 1864 year age ( inclusive ) , Diagnosis primary insomnia symptom least three month . Any clinically significant unstable medical surgical condition ( treat untreated ) . Any history clinically significant abnormality neurological system ( include cognitive disorder significant head injury ) history seizure ( include febrile seizure ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>primary insomnia</keyword>
	<keyword>PSG sleep recording</keyword>
	<keyword>daytime cognitive function</keyword>
	<keyword>Insomnia</keyword>
	<keyword>SB-649868</keyword>
</DOC>